The American Society of Human Genetics (ASHG) is deeply concerned by the Executive Order (EO) issued last week titled “Improving Oversight of Federal Grantmaking.” While ASHG supports efforts to ensure transparency, accountability, and scientific rigor in federally funded research, we are particularly troubled that the EO’s directives risk introducing political considerations into the grantmaking process.... Read More
The recently released White House Office of Science and Technology Policy (OSTP) report, Bold Goals for U.S. Biotechnology and Biomanufacturing, highlights where insights provided by human genetics and genomics are fundamental for the health biotechnology ecosystem and are critical components of the bioeconomy. This report comes after OSTP solicited public input in a Request for... Read More
ASHG recently responded to a select number of questions in a Request for Information (RFI) from the White House Office of Science and Technology Policy (OSTP) on the National Biotechnology and Biomanufacturing Initiative. OSTP released this RFI to seek public input on how advances in biotechnology and biomanufacturing can help support a strong bioeconomy. The insights... Read More
November 8 saw a midterm election during which all members of the House of Representatives and one-third of the Senate were up for re-election. Democrats retained control of the Senate and Republicans ultimately won only a narrow majority in the House. This will usher in at least two years of divided government, and experts anticipate... Read More
The biomedical research system has historically been supported by two main pillars: fundamental research on the mechanisms of disease, largely funded by the National Institutes of Health (NIH), and the pharmaceutical industry, which creates products to treat these conditions. Recent advances in biomedical research and health sciences present an opportunity to change how we understand,... Read More